Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,569.80
(
-0.83%
)
US TECH 100
23,608.80
(
-0.79%
)
Dow Jones
45,918.03
(
-0.66%
)
Brent Oil
108.48
(
1.78%
)
Bitcoin
69,279.01
(
-2.75%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tony111 post# 76468

Thursday, 06/04/2009 6:14:56 PM

Thursday, June 04, 2009 6:14:56 PM

Post# of 257257
If ANDS’ BoD had shareholder value in mind, they probably should have liquidated the company instead of raising more capital and plowing ahead with ANA598, which is another loser program, IMO.

ANDS does not exactly have an impressive drug-discovery/development team; everything the in-house team has produced to date has either failed (ANA975, ANA380, ANA773) or is on the verge of failing (ANA598). Why give more money to a team that evidently doesn’t have what it takes to be successful?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now